Obesity Dosing of High Dose Melphalan in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Deanna Caldwell; Morgan Hopkins; Kate Kelly; Adrienne Fulford; Anargyros Xenocostas; Dr. Uday Deotare

doi:10.1016/j.jtct.2025.12.626

February 1, 2026Transplantation and Cellular Therapy

Obesity Dosing of High Dose Melphalan in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

View at Publisher

Ask AI

Bookmark

Share

Key Points

Obesity affects dosing strategies for high dose melphalan in multiple myeloma treatment.
Key metrics indicate that appropriate dosages are crucial for treatment efficacy and safety.
Analysis evaluates parameters in patients undergoing autologous hematopoietic cell transplant.
The findings underscore the need for personalized treatment plans to enhance outcomes in this patient population.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis assesses dosing effects of high dose melphalan in multiple myeloma, suggesting tailored approaches are needed for patients with obesity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Caldwell et al. (2026) studied this question.

synapsesocial.com/papers/69a760bec6e9836116a2dca3 https://doi.org/10.1016/j.jtct.2025.12.626

View at Publisher

Ask AI

Bookmark

Share

Obesity Dosing of High Dose Melphalan in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Obesity Dosing of High Dose Melphalan in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading